DoH And Sanofi Collaborate To Accelerate Global Vaccine Development In Abu Dhabi

The Department of Health – Abu Dhabi (DoH) has entered into a Memorandum of Understanding (MoU) with Sanofi, a biopharma company focused on research and development. This partnership was formalised at the BIO International Convention 2025 in Boston, USA. The collaboration aims to leverage Abu Dhabi's health-tech ecosystem to advance global vaccine development and strengthen regional manufacturing capabilities.

Dr. Asma Al Mannaei from DoH and Baptiste de Clarens from Sanofi signed the agreement in the presence of Dr. Noura Khamis Al Ghaithi and Laurie Gery. The partnership seeks to expedite vaccine development by utilising advanced technologies and real-time data analysis, aiming to reduce the timeline from research to public availability.

Sanofi's General Manager for Greater Gulf, Vaccines, Baptiste de Clarens, stated, "The Memorandum of Understanding signed with the Department of Health – Abu Dhabi marks an encouraging step towards advancing global health security while reflecting our shared interest in addressing global health challenges through scientific partnership." This agreement will explore how Sanofi's expertise can complement Abu Dhabi's R&D ecosystem.

The collaboration also focuses on streamlining regulatory processes and enhancing manufacturing readiness. It promotes knowledge sharing between local and international experts, aligning with Abu Dhabi’s goal to become a hub for bio- and pharmaceutical innovation. This reflects the emirate’s commitment to proactive, technology-driven healthcare solutions.

Both parties will work on advancing clinical research and optimising resource allocation. They aim to establish foundational terms for funding and access, enhancing healthcare resilience across Abu Dhabi’s sector. These efforts are designed to expand access to quality care for patients both locally and globally.

Dr. Asma Al Mannaei highlighted that this initiative combines Sanofi's scientific expertise with Abu Dhabi's infrastructure. "By combining Sanofi's global scientific expertise with Abu Dhabi's state-of-the-art infrastructure, we set new benchmarks for resilience, innovation and international partnerships," she said.

This partnership underscores a strategic move towards establishing Abu Dhabi as a leading centre for pharmaceutical innovation. It aims to drive transformative change that safeguards community health while contributing to global health security.

With inputs from WAM